Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) . . .
A recent upgrade in how those compounds are stored and shipped out to scientists far and wide has put a state-of-the-art twist on the crucial task.